Table 2.
Summary of outcomes of neuroprotective treatments combined with therapeutic hypothermia in ischemic stroke.
| Reference | Permanent(P)/ Transient (T) Ischemia |
Temperature degree(°C) | Combined Treatment | Aim of study | Yes/No |
|---|---|---|---|---|---|
| Animal | |||||
| [10] | P | 33 | Mk-801 | Enhanced effect | No |
| [11] | T | 30 | Mk-801 | Effective | Yes |
| [12] | T | 30 | Mk-801 | Enhanced effect | Yes |
| [18] | T | 34 | Selfotel | Enhanced effect | No |
| [19] | Repetitive | 34 | Selfotel | Enhanced effect | Yes |
| [21] | T | 35.4 | Magnesium | Enhanced effect | Yes |
| [22] | P | 35 | Magnesium | Enhanced effect | Yes |
| [23] | T | 33-34 | Magnesium | Enhanced effect | Yes |
| [24] | P | 35 | Magnesium | Enhanced effect | No |
| [27] | T | 33 | t-PA | Reduce the side effect of t-PA | Yes |
| [28] | T | 34 | t-PA | Reduce the side effect of t-PA | Yes |
| [29] | T | 32 | Delayed t-PA | Enhanced effect | No |
| [30] | T | 33 | t-PA | Enhanced effect | No |
| [42] | T | 35 | Tacrolimus | Enhancec/expand time window of tacrolimus | Yes |
| [52] | T | 32-33 | Atorvastatin | Enhanced effect/ expand time window of hypothermia |
Yes |
| [57] | T | 35 | Edaravone | Enhanced effect | Yes |
| [65] | T | 34 | Citicoline | Enhanced effect | Yes |
| [25] | T | 33 | Minocycline | Enhanced effect | Yes |
| [48] | P | 34 | Minocycline | Enhanced effect | No |
| [49] | P | 34-35 | Minocycline | Enhanced effect | No |
| [69] | T | 35 | Caffeinol | Enhanced effect | Yes |
| [72] | T | 35 | Chlorpromazine and Promethazine | Enhanced effect | Yes |
| [77] | T | 33 | Methohexital | Enhanced effect | No |
| [84] | T | 36 | Xenon | Enhanced effect | Yes |
| [88] | Incomplete | 35 | Dexmedetomidine | Enhanced effect | No |
| [98] | T | 33 | t-PA and Normobaric Oxygen (NBO) | Enhanced effect | Yes |
| [99] [105] |
T - |
33 31 |
t-PA And normobaric oxygen (NBO) Hyperbaric oxygenation (HBO2) |
Enhanced effect Enhanced effect |
Yes Yes |
| [100] | T | 33 | t-PA and normobaric oxygen (NBO) | reduce the side effect of t-PA | Yes |
| [115] | T | 33.5-35 | Granulocyte-Macrophage Colony-Stimulating Factor (G-CSF) | Enhanced effect | Yes |
| [120] | T | 32 | Insulin-Like Growth Factors -1(IGF-1) | Enhanced effect | Yes |
| [121] | T | 30-33 | Insulin-Like Growth Factors -1(IGF-1) | Enhanced effect | No |
| [128] | P | 33 | Brain-Derived Neurotrophic Factor (BDNF) | Enhanced effect | Yes |
| [133] | T | 33 | Magnesium and Tirilazad | Enhanced effect | Yes |
| [134] | T | 33 | Magnesium and Tirilazad | Effective | Yes |
| [135] | T | 33 | Magnesium and Tirilazad | Enhanced effect | Yes |
| [59] | P | 32-34 | Mannitol | Enhanced effect | No |
| [60] | T | 33 | Mannitol | Enhanced effect | No |
| [137] | T | 30-31 | Albumin | Enhanced effect | Yes |
| [141] | P | 32 | Decompressive Craniectomy | Enhanced effect | Yes |
| [142] | P | 29-31 | Decompressive Craniectomy | Enhanced effect | Yes |
| [147] | T | 35 | PTD-FNK | Enhanced effect | Yes |
| [150] | T | 33 | Gene of Bcl-2 | Expand time window/Enhanced effect | Yes |
| Neuronal culture | |||||
| [78] | - | 22/32 | Thiopentone Sodium (TPS) | Enhanced effect | Yes |
| [93] | - | 33 | Dantrolene | Enhanced effect | Yes |
| Clinical | |||||
| [31] | T | 33 | t-PA | Enhanced effect | No |
| [32] | T | 32-34 | t-PA | Enhanced effect | No |
| [33] | T | <35.5 | t-PA | Feasible/improve outcome | Yes |
| [34] | T | 34.5 | t-PA | Reduce the side effect of tPA | Yes |
| [37] | T | decrease 2 in brain |
Intra-Arterial Recanalization | Feasible and safe | Yes |
| [69] | T | 33-35 | Caffeinol and T-PA | Feasible | Yes |
| [143] | P | 35 | Decompressive Craniectomy | Enhanced effect | Yes |